Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Capital Expenditures (2020 - 2025)

Rani Therapeutics Holdings has reported Capital Expenditures over the past 6 years, most recently at $88000.0 for Q2 2025.

  • Quarterly results put Capital Expenditures at $88000.0 for Q2 2025, up 37.5% from a year ago — trailing twelve months through Dec 2025 was $88000.0 (down 67.16% YoY), and the annual figure for FY2025 was $88000.0, down 67.16%.
  • Capital Expenditures for Q2 2025 was $88000.0 at Rani Therapeutics Holdings, up from $31000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for RANI hit a ceiling of $1.0 million in Q3 2023 and a floor of -$99000.0 in Q2 2021.
  • Median Capital Expenditures over the past 5 years was $85000.0 (2023), compared with a mean of $122647.1.
  • Peak annual rise in Capital Expenditures hit 8433.33% in 2023, while the deepest fall reached 154.65% in 2023.
  • Rani Therapeutics Holdings' Capital Expenditures stood at -$90000.0 in 2021, then skyrocketed by 103.33% to $3000.0 in 2022, then skyrocketed by 5466.67% to $167000.0 in 2023, then crashed by 81.44% to $31000.0 in 2024, then soared by 183.87% to $88000.0 in 2025.
  • The last three reported values for Capital Expenditures were $88000.0 (Q2 2025), $31000.0 (Q4 2024), and $125000.0 (Q3 2024) per Business Quant data.